Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
about
Vitamin D compounds for people with chronic kidney disease not requiring dialysisLarge animal models of cardiovascular diseaseRegulatory circuits controlling vascular cell calcificationVitamin D and osteogenic differentiation in the artery wallEffects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockadeSoluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl ratsChronic Activation of Heme Free Guanylate Cyclase Leads to Renal Protection in Dahl Salt-Sensitive Rats.Vitamin D induces increased systolic arterial pressure via vascular reactivity and mechanical properties.The dualistic role of vitamin D in vascular calcificationsRenal phenotype of ET-1 transgenic mice is modulated by androgensChondro/osteoblastic and cardiovascular gene modulation in human artery smooth muscle cells that calcify in the presence of phosphate and calcitriol or paricalcitolThe mechanism of vascular calcification - a systematic review.Arterial calcification and stiffness in chronic kidney disease.Vitamin D affects survival independently of vascular calcification in chronic kidney disease.Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.Shining D' light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D.Mechanisms and treatment of extraosseous calcification in chronic kidney disease.NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.Vitamin D in patients with chronic kidney disease: a position statement of the Working Group "Trace Elements and Mineral Metabolism" of the Italian Society of Nephrology.The matrix metalloproteinases 2 and 9 initiate uraemic vascular calcifications.Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats.The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure.The importance of intake: a gut feeling.Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease.25-hydroxyvitamin D levels and vascular calcification in predialysis and dialysis patients with chronic kidney disease.Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD.Pulmonary fibrosis in L-NAME-treated mice is dependent on an activated endothelin system.Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure.Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic miceThis article is one of a selection of papers published in the special issue (part 1 of 2) on Forefronts in EndothelinVascular calcification and renal bone disorders
P2860
Q24240439-B92E9C1A-72E1-48D1-8F0F-B8DDB465B563Q26766350-3056F485-E32E-49BA-A953-7E8D986BEAD0Q26825788-88631F76-3F54-40D7-BD5E-BBFA44A0B754Q28284363-4A0FBAB1-6992-4AB4-B592-8F2770E520F6Q28482185-6B40EC08-4E5E-4457-828B-1C64A16B8F10Q28742463-62AEB93E-3C66-4786-9D2D-FC70643E4560Q30315850-7D0911EE-256A-4CE8-9EF8-F519728B0D33Q33748607-6B68C13B-DDF8-4911-9C84-EF21D759AD9BQ35059753-0295D120-3F91-4D21-8598-FCD9509A7816Q35959010-E55928F8-10C4-4E55-AABE-79E38503EA08Q36316104-034FD290-158D-411F-B8F0-A3926AD372EFQ36577167-28823E8C-BAAB-447D-979A-6CD130640629Q36854161-FF8C536A-C678-4728-8EAB-57E34552D502Q37211081-BA887F26-ECDC-41BE-8E27-00E6CFCFFDD6Q37230788-BAFDC83D-41FA-418F-8397-67DF1319FEA3Q37842680-64576F38-F713-48DE-BEA7-A8327FE1375BQ37902504-62186281-0135-4D60-B33E-993F8501C1E1Q38758203-495D9671-A409-40EA-B166-5C31EBCCE428Q38803449-12E57FE2-02BD-436A-B2F2-8DBBAFD22645Q38838486-26B48919-B661-4762-87C5-922D9B37A520Q38878795-BF084167-9153-472F-A173-32AC10428FE9Q40122114-9103D411-700E-4CA2-BBBF-B41611911C90Q41848858-C48221BC-F449-452F-914F-8420B6B055DCQ43799102-3441111A-EE6F-4C59-91E7-93E0E76C1B05Q44621001-5F88B1C3-8546-49CA-B279-5C597BD458F6Q47571217-C19A9731-976E-49E1-AAA4-56F5785081ABQ52916257-7F35BF1D-5DEB-4B1B-B0B4-83CF113F13FBQ54597198-1FEAD314-8EEF-450A-A62E-E108B0CD4DD9Q57570889-A5801964-CC1C-42F4-92E2-FC264351D601Q59100578-94555DA7-0379-427B-B94E-F7957AE092C2
P2860
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@en
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@nl
type
label
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@en
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@nl
prefLabel
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@en
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@nl
P2093
P1476
Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3.
@en
P2093
Barbara Eggert
Claus-Michael Richter
Dieter Haffner
Dominik Müller
Johanna Schwarz
Katja Simon
Michael Godes
Richard Nissel
Uwe Querfeld
P304
P356
10.1097/01.HJH.0000166849.72721.1C
P577
2005-05-01T00:00:00Z